1. Introduction {#sec1}
===============

Sensorineural hearing loss is a common human disorder affecting approximately 275 million people around the world, which occurs because of damaged or deficient cochlear hair cell function ([@bib56]). The human cochlea contains only about 5000 hair cells (HCs) and do not have the capability to self-repair. Genetic defects may cause the hair cells to be abnormal at birth. Additionally, there are many environmental factors, including noise, aging, and ototoxic drugs, which can cause damage to the HCs. Aminoglycoside (AmAn) antibiotics are common clinical drugs characterized by amino sugars with glycosidic linkages. These compounds are widely used throughout the world to treat gram-negative bacterial infections, which are not responsive to conventional antibiotics, such as penicillin. However, AmAn is difficult to metabolize and can be concentrated in the perilymph and endolymph of the inner ear ([@bib39]), which results in irreversible auditory and vestibular ototoxicity ([@bib29], [@bib32], [@bib1], [@bib3], [@bib43], [@bib48]). The abuse of these drugs such as gentamicin, kanamycin, particularly in developing countries has caused millions of people to suffer from ototoxic side effects. The incidence of ototoxicity has been suggested to range from 2% to 45% for adults and 0--2% for infants ([@bib58], [@bib28]). It has been found that there is unusual susceptibility to AmAn ototoxicity related to genetic background in many individuals. In this mini-review, we briefly introduce the molecular mechanism of genetic susceptibility to AmAn ototoxicity hearing loss.

1.1. Aminoglycosides destroy bacteria without harming mammalian cells by irreversibly binding the 30S subunit of the bacterial ribosome {#sec1.1}
---------------------------------------------------------------------------------------------------------------------------------------

The ribosome is a complex molecular machine found within all living cells, which serves as the site of biological protein synthesis (translation). Ribosomal proteins and rRNAs are arranged into two distinct ribosomal pieces of different sizes, known generally as the large and small subunit of the ribosome. The ribosomal subunits of prokaryotes and eukaryotes are very similar. Prokaryotes have 70S ribosomes, each consisting of a small (30S) and a large (50S) subunit, while eukaryotes have 80S ribosomes consisting of a 40S and a 60S subunit ([@bib63], [@bib16], [@bib79]). The structural differences between the bacterial 70S ribosomes and eukaryotic 80S ribosomes have been exploited to create antibiotics to combat bacterial infections without harming cells of the infected person ([@bib36]). Aminoglycosides take effect by directly binding to the base pairs C1409--G1491 at the A-site of bacterial 16S rRNA ([Fig. 1](#fig1){ref-type="fig"}A), which acts as an essential part of the decoding site, and this interaction results in protein mistranslation or premature termination of protein synthesis ([@bib18], [@bib62]).Fig. 1The sites of m.1555A\>G and m.1494C\>T mutations in the decoding region of human mitochondrial 12S rRNA. The A-site is shown at the secondary structure of *E. coli* 16S rRNA in A. The corresponding position of human mitochondrial 12S rRNA is shown as the wild-type version and in the version carrying the m.1555A\>G and m.1494C\>T mutations in B, C and D.Fig. 1

Ribosomes are also found in chloroplasts and mitochondria of eukaryotes, and are similar to bacterial ribosomes. According to the endosymbiotic theory, these organelles are believed to be descendants of bacteria that became incorporated into eukaryotic cells for the implementation of oxidative mechanisms ([@bib76], [@bib70]). Mitochondria are thought to originate from α-purple bacteria. During the course of their evolution, the endosymbiont transferred many of its essential genes to the nuclear chromosomes of eukaryotes and developed into the present-day mitochondria in the eukaryotic cell. Nevertheless, mitochondria still carry hallmarks of their bacterial ancestors. For instance, mitochondria use fMet-tRNA as an initiator of protein synthesis. Mammalian mitochondrial ribosomes have small 28S and large 39S subunits, forming a 55S protein complex, which is active in mitochondria and functions to translate mitochondrial mRNAs encoded in mtDNA ([@bib15]). Even though mitochondria ribosomes are similar to bacterial ribosomes, normal cells show low toxicity to regular dosages of AmAn. This is because mitochondria are surrounded by a double membrane which does not easily admit these antibiotics into the organelle. More importantly, mammalian mitochondrial ribosomes possess an A-to-G substitution in the aminoglycoside binding site in 16S rRNA, leading to the significantly reduced toxicity of AmAn in eukaryotic cells ([@bib41], [@bib36], [@bib32], [@bib69], [@bib4], [@bib26], [@bib42]).

1.2. Mitochondrial DNA mutations m.1555A\>G and m.1494C\>T are associated with aminoglycoside ototoxicity {#sec1.2}
---------------------------------------------------------------------------------------------------------

Mitochondria have their own genome with a modified genetic code. The mammalian mitochondrial genome is transmitted exclusively through the female germ line. Indeed, pedigree analysis has shown that the aminoglycoside susceptibility exhibits a maternally inherited transmission. The most well studied mutations are m.1555A\>G and m.1494C\>T in the 12S rRNA gene of the 39S subunit ([@bib59], [@bib66], [@bib31]). [@bib65] first suggested the molecular basis of ototoxic hearing loss by analyzing the mitochondrial genome of three Chinese pedigrees and a large Arab-Israeli pedigree with maternally inherited non-syndromic hearing loss. The m.1555A\>G in the 12S rRNA gene was identified in these matrilineal subjects, but not found in 278 control subjects ([@bib65]). As shown in [Fig. 1](#fig1){ref-type="fig"}, the A nucleotide at the 1555 position in the 12S rRNA gene in human mitochondria is equivalent to position 1491 in the 16S rRNA gene in wild-type *Escherichia coli* ([@bib7]). When the 1555 A is mutated to G, the secondary structure of 12S rRNA more closely resembles the corresponding region of 16S rRNA in *E. coli* ([Fig. 1](#fig1){ref-type="fig"}C). Thus, it was speculated that this newly generated G-C pair creates a binding site for aminoglycoside. Indeed, Guan et al. reported that the m.1555A\>G mutation alters the binding properties of aminoglycosides at the A-site of rRNA and leads to conformational changes in 12S rRNA. Families with inherited patterns of deafness carrying the m.1555A\>G mutation have subsequently been reported worldwide, including in Asian, Caucasian, and African populations, as well as in many sporadic individuals ([@bib57], [@bib64], [@bib27], [@bib19], [@bib50], [@bib44], [@bib83], [@bib47], [@bib72], [@bib6], [@bib11], [@bib78], [@bib54], [@bib37], [@bib45]). Zhao et al. identified a homoplastic mutation at position 1494 (m.1494C\>T) in the mitochondria genome in a large Chinese pedigree with ototoxic deafness ([@bib85]). It is reasonable to conclude that this alteration also contributes to the hypersensitivity to AmAn, since m.1494 is the corresponding position of m.1555 at the highly conserved A-site of 12S rRNA gene ([Fig. 1](#fig1){ref-type="fig"}D). In addition, the researchers found both the severity of deafness and the age of onset vary among subjects in the absence of AmAn exposure, and that the administration of AmAn can induce or aggravate hearing loss in matrilineal relatives. This finding was subsequently validated by additional studies in both Chinese ([@bib77], [@bib14], [@bib38], [@bib84], [@bib88]) and Spanish pedigrees ([@bib68]).

Although the m.1555A\>G and m.1494C\>T mutations are located at corresponding positions and both mutations were reported in hearing loss subjects among various ethnic backgrounds, the m.1555A\>G mutation is likely to be more frequent than m.1494C\>T. Moreover, there is a distinctly ethnic and geographical pattern of the m.1555A\>G mutation in hearing loss. Considering only drug-induced deafness, the incidence of the m.1555A\>G mutation was approximately 33% in two Japanese ethnic groups ([@bib75], [@bib61]), 13%, 12.29%, 10.4%, and 5% in four Chinese ethnic groups ([@bib41], [@bib53], [@bib54], [@bib49]), and 17% in two white ethnic groups from the United States and Spain ([@bib30], [@bib27]). However, the frequency of the m.1494C\>T mutation is much lower. In 1642 Chinese children subjects who suffered from hearing loss, the frequency of the m.1555A\>G mutation was 3.96% while the frequency of the m.1494C\>T mutation was only 0.18% ([@bib54]). Additionally, in a study of sporadic Spanish hearing-impaired subjects, only three cases were found to have the m.1494C\>T mutation among 1340 people ([@bib68]).

1.3. Other mitochondrial DNA mutations related to aminoglycoside ototoxicity {#sec1.3}
----------------------------------------------------------------------------

Based on sequence analysis of the complete mitochondrial genome, several additional mitochondrial DNA mutations were found to be associated with ototoxic hearing loss. Zhao et al. reported that the m.1095T\>C mutation correlated with ototoxicity and non-syndromic hearing loss in three Chinese families with ototoxic hearing loss ([@bib87]). This T-to-C mutation, located in the 12S rRNA gene which disrupts the conserved stem loop of helix 25 ([@bib60]), was found in affected individuals, but not in 364 Chinese control individuals. The alternation may affect the initiation of mitochondrial protein synthesis and, consequently, result in mitochondrial dysfunction ([@bib73]). Moreover, insertion or deletion at the 961 position was reported to be associated with ototoxicity deafness in several genetically unrelated families ([@bib5], [@bib10], [@bib71], [@bib46]). This position is located at the C-cluster between loops 21 and 22 of 12S rRNA ([@bib60]). However, this region is not evolutionarily conserved and its functions remain unclear, especially its interaction with aminoglycoside in bacterial homologs. Furthermore, after screening 12S rRNA gene sequences collected from Chinese children diagnosed with hearing loss, mitochondrial DNA mutations including m.745A\>G, m.792C\>T, m.801A\>G, m.839A\>G, m.856A\>G, m.1027A\>G, m.1192C\>T, m.1192C\>A, m.1310C\>T, m.1331A\>G, m.A374A\>G, m.1452T\>C and m.1537C\>T were suggested to be related to AmAn ototoxicity or non-syndromic hearing loss ([@bib50], [@bib47], [@bib46], [@bib54]). All of these mutations are in highly conserved nucleotides in the 12S rRNA and were not found in the 449 control samples. However, the frequencies of these variants were very low. For instance, the incidence of the mutation 1095C\>T was 0.61% and an insertion or deletion at the 961 position was 1.8% in a large Chinese pediatric population ([@bib54]). The frequencies of the other mutations were even lower ([@bib47], [@bib46], [@bib54], [@bib81]).

1.4. Potential pathophysiological mechanisms of aminoglycoside ototoxicity {#sec1.4}
--------------------------------------------------------------------------

A lot of research has been performed to substantiate the theory of maternally transmitted ototoxic hearing loss ([Fig. 2](#fig2){ref-type="fig"}). The mutations m.1555A\>G and m.1494C\>T cause a local conformational change at the A-site of 12S rRNA ([@bib67]), which impacts the accuracy and efficiency of codon interaction and subsequently disrupts the synthesis of mitochondrial protein ([@bib40]). As reported, the mutations m.1555A\>G and m.1494C\>T induce the mistranslation of mitochondrial proteins in patient-derived lymphocyte cell lines, reducing the rate of mitochondrial protein labeling 30--40% ([@bib33], [@bib35]). In addition, these cells exhibited a decline in ATP generation and an increase in production of reactive oxygen species (ROS) ([@bib80]).Fig. 2Schematic representation of pathways leading to hearing loss associated with mitochondrial 12S rRNA mutations. AmAn is the primary factor inducing the loss of HCs, mtDNA haplogroups and the nuclear modifier genes play important roles in the phenotype manifestation of hearing loss.Fig. 2

The mild biochemical defects caused by the m.1555A\>G and m.1494C\>T mutations are the primary factors in the development of hearing impairment, but are not themselves sufficient to produce a clinical phenotype. An RNA-directed chemical modification experiment showed that the m.1555A\>G mutation increased the binding of six aminoglycosides to the 12S rRNA and changed the patterns of chemical modifications by dimethyl sulfate (DMS) in the presence of aminoglycosides. Moreover, the accumulation of AmAn in the cochlea and vestibular system worsens defects in mitochondrial protein synthesis. As previously reported, aminoglycosides selectively concentrate in the cochlea and vestibular system and are taken up into lysosomes and mitochondria in HCs ([@bib67]). AmAn may impair mitochondrial translation in cochlear cells in susceptible subjects carrying the m.1555A\>G or m.1494C\>T mutations. Guan et al. found that the growth of cytoplasmic hybrid (cybrid) cells carrying the m.1555A\>G or m.1494C\>T mutation were significantly inhibited by paromomycin. Aminoglycosides caused an additional decrease (∼30%) in the rate of protein synthesis in cells carrying m.1555A\>G or m.1494C\>T mutations, leading to the overall mitochondrial translation rate being reduced below the minimal level that required for normal cell function ([@bib33], [@bib34], [@bib85]). The decrease in protein synthesis subsequently induces the apoptosis of HCs. As reported by Ding et al., the damage begins at the base of the cochlea and progresses toward the apex after systemic administration of aminoglycoside antibiotics, meaning that outer hair cell loss precedes inner hair cell loss. Moreover, aminoglycosides can also induce acute physiological effects on the auditory nerve, thus inducing the deafness phenotype ([@bib23], [@bib21], [@bib22], [@bib20], [@bib24], [@bib25], [@bib86]).

However, in the absence of aminoglycosides, subjects bearing the m.1555A\>G mutation can exhibit considerable phenotypic variation ([@bib65], [@bib57], [@bib27], [@bib50], [@bib83], [@bib72], [@bib11], [@bib2]). Some Chinese pedigrees carrying the m.1555A\>G mutation exhibit very low penetrance of hearing loss ([@bib83], [@bib17], [@bib72], [@bib11]), while a large Arab-Israeli pedigree carrying the m.1555A\>G mutation showed high penetrance of hearing loss ([@bib9]). After analyzing the haplogroups of 69 Chinese pedigrees carrying the m.1555A\>G mutation, Lu et al. found that all of these Chinese pedigrees belonged to ten different haplogroups, including A, B, C, D, F, G, M, N, R, and Y ([@bib55]). Other studies reported that some Spanish pedigrees carrying the m.1555A\>G mutation belonged to various European haplogroups such as H, I, J, K, T, U, V, and L ([@bib74], [@bib19]). The main haplogroups among the Chinese and Spanish pedigrees carrying the m.1555A\>G mutation were found to be D and H, while the haplogroups A, C, G, R and Y were found to be rare in these families. Among the 69 Chinese pedigrees, 11 of them were haplogroup B, which displayed higher penetrance than other families. These results indicate that mitochondrial haplogroups play important roles in the phenotypic manifestation of the m.1555A\>G and m.1494C\>T mutations.

Further, Qian et al. showed that the rate of mitochondrial protein synthesis was reduced by approximately 28% and 50% on average in lymphocyte cell lines isolated from nine asymptomatic and ten symptomatic subjects, respectively, from an Arab-Israeli family carrying the m.1555A\>G mutation ([@bib33], [@bib35]). Notably, no significant difference in the average protein reduction was found in cybrid cell lines between the two groups under a constant nuclear background (35% vs 37% reduced). These data indicate that nuclear-encoded modifier genes also affect the biochemical phenotype of cells carrying the mutations. Extensive genome-wide link-age studies in Arab-Israeli and Spanish-Italian families has shown that mutations in nuclear-encoded modifier genes such as MTO1, GTPBP3 and TRMU may induce mitochondrial tRNA metabolic disorders in subjects carrying the m.1555A\>G or m.1494C\>T mutations ([@bib51], [@bib52], [@bib8], [@bib82], [@bib13], [@bib12]).

According to the accumulated genetic and biochemical evidence, we propose a mechanism for maternally transmitted aminoglycoside ototoxicity ([Fig. 2](#fig2){ref-type="fig"}). We hypothesize that mutations in mitochondrial 12S rRNA, especially the mutations m.1555A\>G or m.1494C\>T, induce defects in mitochondrial protein synthesis. Aminoglycosides are selectively concentrated in the cochlea and vestibular system cell mitochondria. These drugs worsen defects the mitochondrial protein synthesis caused by the 12S rRNA m.1555A\>G or m.1494C\>T mutations. The translational defects result in the apoptosis of HCs in the cochlea and vestibular system, which consequently induces the deafness phenotype. Additionally, mutations in nuclear modifier genes and mitochondrial haplogroups can aggravate the phenotype of hearing impairment.

1.5. Prevention of aminoglycoside ototoxicity {#sec1.5}
---------------------------------------------

Mutations in the 12S rRNA gene are the molecular mechanism of aminoglycoside ototoxicity-induced hearing loss. Approximately 17% of ototoxicity subjects were found to have mutations in the 12S rRNA gene. In order to mitigate the negative effect of aminoglycosides, we can predict the ototoxicity risk of individuals by assessing their pedigree or by screening their 12S rRNA gene prior to the administration of AmAn. Medical professionals should ask the patients whether they have a family history of AmAn-induced deafness and screen for mutations in the 12S rRNA gene of the patients or their family members. Carriers of mutations in this gene should avoid exposure to AmAn and use alternative medications for antibiotic treatment to avoid the possibility of inducing ototoxic hearing loss. This will reduce the risk of ototoxicity and improve aminoglycoside antibiotic therapy.

However, aminoglycosides cannot be completely replaced by equally effective or less ototoxic drugs at present and effective alternatives are not always available. Thus, ototoxicity is still a risk to people. Efforts have been undertaken to protect the inner ear from ototoxicity. As ROS play a critical role in mediating aminoglycoside ototoxicity, administration of antioxidants is considered to be the most practical method. A large number of such compounds, some of which are classified as food supplements, can be safely administered in order to relieve stressed cells. Another approach to reduce drug-induced ototoxicity is to inhibit the transporter that selectively uptakes the ototoxic drug into the inner ear. However, it will be crucial to identify at risk patients through careful monitoring in clinical environments. The most promising therapy may be precision medicine, which would diagnose and/or cure the patients selectively at the molecular level.

Further, studies of nuclear-encoded modifying genes have provided insights into the mechanisms of genetic interaction and greatly enriched the understanding of mitochondria related disorders. We believe that the rapidly advancing field of understanding how modifying genes affect phenotypes promises many more advances to come, which can provide further understanding of mitochondrial mutation-related aminoglycoside ototoxicity, as well as identify potential therapeutic targets.
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